Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in HFrEF (VICTORIA)
NCT02861534Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Vericiguat oral suspension (Formulation 4) in heart failure with reduced ejection fraction (HFrEF), sponsored by Merck & Co.. Started Sep 2016; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02861534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861534.